Cat. No. 3130
Alternative Name: CBN
Chemical Name: 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol
Biological ActivityCB2 and CB1 receptor agonist (Ki values are 126 and 211 nM respectively). Inhibits adenylyl cyclase (EC50 values are 120 and 261 nM for CB1 and CB2 receptors respectively) and suppresses immune cell function. Major constituent of cannabis; displays little or no psychotropic activity.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Rhee et al (1997) Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylyl cyclase. J.Med.Chem. 40 3228. PMID: 9379442.
Herring et al (1998) Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem.Pharmacol. 55 1013. PMID: 9605425.
Zygmunt et al (2002) Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J.Neurosci. 22 4720. PMID: 12040079.
If you know of a relevant citation for this product please let us know.
Keywords: Cannabinol, supplier, cannabinoids, CB1, CB2, receptors, agonists, not, psychoactive
Find multiple products by catalog number
New Products in this Area
Selective GPR55 antagonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.